{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:25Z","timestamp":1792712185924,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300\u00a0mg) and palonosetron (0.5\u00a0mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5\u00a0days after chemotherapy. Incremental costs including treatment costs and treatment failure management cost as well as incremental effects including quality adjusted life days (QALDs) and emesis-free days were compared between NEPA and the comparator arms. The primary outcomes were cost per avoided emetic event and cost per QALDs gained.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>NEPA was dominant (more effective and less costly) against aprepitant combined with palonosetron, and fosaprepitant combined with granisetron, while, compared to generic aprepitant plus ondansetron, NEPA showed an incremental cost per avoided emetic event of \u20ac33 and cost per QALD gained of \u20ac125.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>By most evaluations, NEPA is a dominant or cost-effective treatment alternative to current antiemetic standards of care in Spain during the first 5\u00a0days of chemotherapy treatment in cancer patients, despite the introduction of generics. These results are in line with previously reported analyses throughout different international settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07339-1","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T06:18:47Z","timestamp":1662617927000},"page":"9307-9315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2829-5563","authenticated-orcid":false,"given":"Jonas","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Piovesana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Turini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,8]]},"reference":[{"key":"7339_CR1","doi-asserted-by":"crossref","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E,  Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) MASCC and ESMO guideline update or the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133","DOI":"10.1093\/annonc\/mdw270"},{"key":"7339_CR2","unstructured":"Base de Datos de medicamentos del Consejo General de Farmac\u00e9uticos (BOTPLUS). Available at: https:\/\/botplusweb.farmaceuticos.com\/"},{"key":"7339_CR3","doi-asserted-by":"crossref","unstructured":"Aapro M, Karthaus Meinolf, Schwartzberg L, Rossi G, Rizzi G, Borroni ME, Palmas M, Rugo H (2014) Phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron in preventing chemotherapy-induced nausea and vomiting (CINV) during repeated moderately emetogenic chemotherapy (MEC) cycles. Ann Oncol 25:1328\u20131333","DOI":"10.1093\/annonc\/mdu101"},{"issue":"8","key":"7339_CR4","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 23(8):1986\u20131992","journal-title":"Ann Oncol."},{"issue":"15","key":"7339_CR5","doi-asserted-by":"publisher","first-page":"12083","DOI":"10.1200\/JCO.2020.38.15_suppl.12083","volume":"38","author":"M Aapro","year":"2020","unstructured":"Aapro M, Chrapava M, Curca RO et al (2020) Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): results of the Results of the Nausea\/Emesis Registry in Oncology (NERO). J Clin Oncol 38(15):12083","journal-title":"J Clin Oncol"},{"issue":"6","key":"7339_CR6","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scotte F, Escobar Y et al (2021) practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26(6):e1073\u2013e1082","journal-title":"Oncologist"},{"key":"7339_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13716","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist. https:\/\/doi.org\/10.1002\/onco.13716","journal-title":"Oncologist"},{"key":"7339_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1758834016654902","volume":"8","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O (2016) Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol 8:396\u2013406. https:\/\/doi.org\/10.1177\/1758834016654902","journal-title":"Ther Adv Med Oncol"},{"key":"7339_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00520-007-0349-1","volume":"16","author":"L Annemans","year":"2008","unstructured":"Annemans L, Strens D, Lox E, Petit C, Malonne H (2008) Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium Supportive care in cancer\u202f: official journal of the Multinational Association of. Support Care Cancer 16:905\u2013915. https:\/\/doi.org\/10.1007\/s00520-007-0349-1","journal-title":"Support Care Cancer"},{"key":"7339_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, Nickel K, Corman S, Turini M, Binder G (2020) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer 28:857\u2013866. https:\/\/doi.org\/10.1007\/s00520-019-04824-y","journal-title":"Support Care Cancer"},{"key":"7339_CR11","volume-title":"Fixed combination netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in Germany and Greece Spain","author":"FEJ Bourhis","year":"2018","unstructured":"Bourhis FEJ, Ruffo P, D\u2018Agostino P, Turini M. (2018) Fixed combination netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in Germany and Greece Spain. , ISPOR, Barcelona"},{"key":"7339_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","volume":"19","author":"TA Burke","year":"2011","unstructured":"Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19:131\u2013140. https:\/\/doi.org\/10.1007\/s00520-009-0797-x","journal-title":"Support Care Cancer"},{"key":"7339_CR13","doi-asserted-by":"publisher","first-page":"212298","DOI":"10.7573\/dic.212298","volume":"6","author":"H Cawston","year":"2017","unstructured":"Cawston H, Bourhis F, Eriksson J, Ruffo P, D\u2019Agostino P, Turini M, Schwartzberg L, McGuire A (2017) NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 6:212298. https:\/\/doi.org\/10.7573\/dic.212298","journal-title":"Drugs Context."},{"key":"7339_CR14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","volume":"15","author":"L Cohen","year":"2007","unstructured":"Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Supportive care in cancer\u202f: official journal of the Multinational Association of. Support Care Cancer 15:497\u2013503. https:\/\/doi.org\/10.1007\/s00520-006-0173-z","journal-title":"Support Care Cancer"},{"issue":"1","key":"7339_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3111\/13696998.2010.547237","volume":"14","author":"C Craver","year":"2011","unstructured":"Craver C et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14(1):87\u201398","journal-title":"J Med Econ"},{"key":"7339_CR16","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00520-015-2809-3","volume":"23","author":"Y Escobar","year":"2015","unstructured":"Escobar Y, Cajaraville G, Virizuela JA, \u00c1lvarez R, Mu\u00f1oz A, Olariaga O, Tam\u00e9s MJ, Muros B, Lecumberri MJ, Feliu J, Mart\u00ednez P, Adansa JC, Mart\u00ednez MJ, L\u00f3pez R, Blasco A, Gasc\u00f3n P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23:2833\u20132840. https:\/\/doi.org\/10.1007\/s00520-015-2809-3","journal-title":"Support Care Cancer"},{"key":"7339_CR17","doi-asserted-by":"publisher","unstructured":"Escobar \u00c1lvarez Y, De Castro Carpe\u00f1o J, Bell D, Drago A, Franceschetti A (2021) Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain. Clin Translat Oncol https:\/\/doi.org\/10.1007\/s12094-021-02623-8","DOI":"10.1007\/s12094-021-02623-8"},{"key":"7339_CR18","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1007\/s00520-012-1448-1","volume":"20","author":"P Fern\u00e1ndez-Ortega","year":"2012","unstructured":"Fern\u00e1ndez-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Su\u00e1rez C, Zorrilla I, G\u00f3mez J, Zabaleta P, Nocea G, Llombart-Cussac A (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients\u2019 quality of life. Support Care Cancer 20:3141\u20133148. https:\/\/doi.org\/10.1007\/s00520-012-1448-1","journal-title":"Support Care Cancer"},{"key":"7339_CR19","doi-asserted-by":"crossref","unstructured":"Giuliani I BA (2019) Netupitant plus palonosetron (NEPA) for the prophylaxis of chemotherpy-induced nausea and vomiting (CINV) in highly and moderately (AC-based chemotherapy) emetogenic cancer treatment: a cost-effective choice, June 21\u201323, San Fransisco, California, USA, MASCC Annual conference","DOI":"10.1080\/14737167.2019.1650644"},{"key":"7339_CR20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1093\/annonc\/mdu096","volume":"25","author":"RJ Gralla","year":"2014","unstructured":"Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333\u20131339. https:\/\/doi.org\/10.1093\/annonc\/mdu096","journal-title":"Ann Oncol"},{"key":"7339_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/bf01880641","volume":"4","author":"SM Grunberg","year":"1996","unstructured":"Grunberg SM, Boutin N, Ireland A, Miner S, Silveira J, Ashikaga T (1996) Impact of nausea\/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer 4:435\u2013439. https:\/\/doi.org\/10.1007\/bf01880641","journal-title":"Support Care Cancer"},{"key":"7339_CR22","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00520-010-0915-9","volume":"19","author":"A Haiderali","year":"2011","unstructured":"Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect\/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19:843\u2013851. https:\/\/doi.org\/10.1007\/s00520-010-0915-9","journal-title":"Support Care Cancer"},{"key":"7339_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/jco.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy Journal of clinical oncology\u202f: official journal of the American Society of. Clin Oncol 15:103\u2013109. https:\/\/doi.org\/10.1200\/jco.1997.15.1.103","journal-title":"Clin Oncol"},{"key":"7339_CR24","doi-asserted-by":"crossref","unstructured":"Hesketh P RG, Palmas M, Alyasova A, Gralla R. (2013) Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevenention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenenic chemotherapy (HEC), Chicago, Illionis, USA. ASCO Annual meeting","DOI":"10.1200\/jco.2013.31.15_suppl.9512"},{"key":"7339_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdh110","volume":"15","author":"A Ihbe-Heffinger","year":"2004","unstructured":"Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Th\u00f6dtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526\u2013536. https:\/\/doi.org\/10.1093\/annonc\/mdh110","journal-title":"Ann Oncol"},{"key":"7339_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1517\/14656566.2013.776541","volume":"14","author":"MC Janelsins","year":"2013","unstructured":"Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR (2013) Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother 14:757\u2013766. https:\/\/doi.org\/10.1517\/14656566.2013.776541","journal-title":"Expert Opin Pharmacother"},{"key":"7339_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","volume":"722","author":"K Jordan","year":"2014","unstructured":"Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197\u2013202. https:\/\/doi.org\/10.1016\/j.ejphar.2013.09.073","journal-title":"Eur J Pharmacol"},{"key":"7339_CR28","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2217\/fon-2020-0187","volume":"16","author":"M Karthaus","year":"2020","unstructured":"Karthaus M, Oskay-\u00d6zcelik G, W\u00fclfing P, Hielscher C, Guth D, Zahn MO, Flahaut E, Schilling J (2020) Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life. Future Oncol (London, England) 16:939\u2013953. https:\/\/doi.org\/10.2217\/fon-2020-0187","journal-title":"Future Oncol (London, England)"},{"issue":"Suppl 2","key":"7339_CR29","first-page":"458","volume":"19","author":"RL Knoth","year":"2011","unstructured":"Knoth RL et al (2011) Health care costs in chemotherapy induced nausea and vomiting: a retrospective analysis of a commercially insured U.S. patient population. Support Care Cancer 19(Suppl 2):458","journal-title":"Support Care Cancer"},{"key":"7339_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M (2013) Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat 142:101\u2013107. https:\/\/doi.org\/10.1007\/s10549-013-2727-3","journal-title":"Breast Cancer Res Treat"},{"key":"7339_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.402","volume-title":"Netupitant and palonosetron (NEPA) is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Singapore","author":"SL Lim","year":"2019","unstructured":"Lim SL, Loh KWJ, Boisseau S, Ho WT, Qasuri M, D\u2019Agostino P, Turini M, Bourhis F, Eriksson J, Hadjiat Y (2019) Netupitant and palonosetron (NEPA) is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting (CINV) in Singapore. ISPOR, Copenhagen"},{"key":"7339_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejca.2006.09.019","volume":"43","author":"F Lordick","year":"2007","unstructured":"Lordick F, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R (2007) Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer (Oxford England: 1990) 43:299\u2013307. https:\/\/doi.org\/10.1016\/j.ejca.2006.09.019","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"issue":"19","key":"7339_CR33","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1200\/JCO.2010.34.2816","volume":"29","author":"DK Mayer","year":"2011","unstructured":"Mayer DK et al (2011) Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 29(19):2683\u20132688","journal-title":"J Clin Oncol"},{"key":"7339_CR34","unstructured":"Chemotherapy-induced nausea and vomiting (CINV) duration as a predictor of later-cycle CINV\nRudolph M Navari, Gary Binder, Eric J Roeland, Alexander Molassiotis, Kathryn J. Ruddy, Thomas W LeBlanc, Dwight Kloth, Silvia Sebastiani, PhD8, Marco Turini, Ravi Potluri, Luke M Schmerold, Xing Liu, Lee Schwartzberg. SASC Dec -11 virtual meeting PS13-27  https:\/\/www.abstractsonline.com\/pp8\/#!\/9223\/presentation\/1480"},{"key":"7339_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/onco.13620","volume":"26","author":"RM Navari","year":"2021","unstructured":"Navari RM, Ruddy KJ, LeBlanc TW, Nipp R, Clark-Snow R, Schwartzberg L, Binder G, Bailey WL, Potluri R, Schmerold LM, Papademetriou E, Roeland EJ (2021) Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin. Oncologist 26:325\u2013331. https:\/\/doi.org\/10.1002\/onco.13620","journal-title":"Oncologist"},{"key":"7339_CR36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1080\/13696998.2019.1620244","volume":"22","author":"SH Park","year":"2019","unstructured":"Park SH, Binder G, Corman S, Botteman M (2019) Budget impact of netupitant\/palonosetron for the prevention of chemotherapy-induced nausea and vomiting. J Med Econ 22:840\u2013847. https:\/\/doi.org\/10.1080\/13696998.2019.1620244","journal-title":"J Med Econ"},{"key":"7339_CR37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::aid-cncr2820640525>3.0.co;2-r","volume":"64","author":"CF Pollera","year":"1989","unstructured":"Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis Definition and validation of a predictive logistic model. Cancer 64:1117\u20131122. https:\/\/doi.org\/10.1002\/1097-0142(19890901)64:5%3c1117::aid-cncr2820640525%3e3.0.co;2-r","journal-title":"Cancer"},{"key":"7339_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL (2017) Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol 8:19. https:\/\/doi.org\/10.3389\/fphar.2017.00019","journal-title":"Front Pharmacol"},{"key":"7339_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015645","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, Saibene G, Nardulli P, Di Turi R, Bonizzoni E, Scolari F, Perrone T, Croce D, Celio L (2017) Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open 7:e015645. https:\/\/doi.org\/10.1136\/bmjopen-2016-015645","journal-title":"BMJ Open"},{"key":"7339_CR40","doi-asserted-by":"crossref","unstructured":"Schwartzberg LN RM, Ruddy KJ, LeBlanc TW, Clark-Snow RA, Wickham RS, Binde RG, Bailey W, Turini M, Potluri RC, Schmerold LM, Roeland E (2020) Work loss and activity impairment due to duration of nausea and vomiting in patients with breast cancer receiving CINV Prophylaxis, Virtual, May 29\u201331 ASCO Annual meeting","DOI":"10.1200\/JCO.2020.38.15_suppl.e24133"},{"key":"7339_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/jco.1999.17.1.344","volume":"17","author":"DJ Stewart","year":"1999","unstructured":"Stewart DJ, Dahrouge S, Coyle D, Evans WK (1999) Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344\u2013351. https:\/\/doi.org\/10.1200\/jco.1999.17.1.344","journal-title":"J Clin Oncol"},{"key":"7339_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer Supportive care in cancer\u202f: official journal of the Multinational Association of. Support Care Cancer 13:219\u2013227. https:\/\/doi.org\/10.1007\/s00520-004-0710-6","journal-title":"Support Care Cancer"},{"key":"7339_CR43","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212285","volume":"4","author":"M Turini","year":"2015","unstructured":"Turini M, Piovesana V, Ruffo P, Ripellino C, Cataldo N (2015) An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context 4:212285. https:\/\/doi.org\/10.7573\/dic.212285","journal-title":"Drugs Context"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07339-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07339-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T10:49:20Z","timestamp":1667472560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07339-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["7339"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07339-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,8]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Jonas Nilsson and Jennifer Eriksson are employees of Icon plc. Icon plc. received funding from Helsinn Healthcare SA for study design, execution, analysis and manuscript development. Vittoria Piovesana and Marco Turini are employees of Helsinn Healthcare SA. Helsinn Healthcare commercializes AKYNZEO\u00ae (netupitant palonosetron) worldwide. AKYNZEO\u00ae (netupitant palonosetron) is the subject of the present economic analysis. Matti Aapro has been a consultant for many companies developing antiemetics, including Helsinn.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}